Probiotics for Lupus (SLE)

Probiotics have not been shown to help lupus. The idea is reasonable, because people with lupus have a different gut microbiome, but a 2023 systematic review found 22 studies, mostly in mice and cell cultures; its only randomised trial in people was a 60-day Indonesian synbiotic trial (a probiotic plus a prebiotic fibre) that reported lower disease activity scores [1][2]. Since then, a second synbiotic trial reported lower scores after 2 months [3], while a 13-week trial of probiotic yogurt found no change compared with plain yogurt [4].

A 2024 meta-analysis pooled four small Chinese-language trials of probiotic preparations added to standard care and found SLEDAI scores 2.3 points lower [5], but those reports can't be checked easily and none was independently repeated. Our verdict is insufficient, with limited evidence. For other add-ons with more research behind them, see the omega-3, vitamin D and DHEA pages, and the lupus overview.

Studies of the lupus gut find an altered microbiome. A review of five studies in 288 people found that active lupus came with more Lactobacillus, Streptococcus, Veillonella and Blautia, among others, than lupus in remission, and that Faecalibacterium, Roseburia and Ruminococcus gnavus differed between the two states [6]. Researchers hope that shifting the balance of gut bacteria could calm the immune system.

Laboratory work supports the idea. When immune cells from 20 people newly diagnosed with lupus were exposed to Lactobacillus rhamnosus and Lactobacillus delbrueckii in a dish, markers of regulatory T cells (FOXP3, IL-10, TGF-beta) rose and the inflammatory signal IL-6 fell [7]. A review of 12 studies in lupus-prone mice found that several Lactobacillus strains lowered inflammatory cytokines and delayed autoantibody production [8]. In the 60-day human synbiotic trial, IL-6 fell, and gene-based predictions suggested that butyrate metabolism by gut bacteria rose [2].

Results in mice and cell cultures often fail in people, and the human data so far are mostly blood markers. In the synbiotic trial, IL-17 did not change [2]. A 2026 meta-analysis of 12 trials across autoimmune diseases found probiotics lowered IL-6 and hs-CRP, but its subgroup results were reported for rheumatoid arthritis and multiple sclerosis, and it gives no lupus-specific result [9].

"More Lactobacillus" is not automatically better either: in the microbiome review, Lactobacillus was among the genera that were higher during active lupus [6]. Strains behave differently, so a result with one product can't be assumed for another. See the main probiotics page for how strains and doses differ.

No two lupus trials used the same product. The Indonesian trial gave one capsule a day of 3 billion CFU of Lactobacillus helveticus R0052, Bifidobacterium infantis R0033 and Bifidobacterium bifidum R0071, with 80 mg of fructo-oligosaccharides, for 60 days [2]. The Iranian synbiotic trial combined Streptococcus thermophilus, five Lactobacillus species, three Bifidobacterium species and fructo-oligosaccharides for 2 months; its abstract does not give the dose [3].

The yogurt trial used 200 g a day of yogurt containing Lactobacillus rhamnosus and Bifidobacterium bifidum for 13 weeks [4]. The Chinese trials in the meta-analysis used probiotic preparations, mostly Bifidobacterium and Lactobacillus combinations, alongside standard treatment [5]. Probiotic labels state the number of live bacteria as colony-forming units (CFU), but labelling practices are inconsistent [11], so match the strains and CFU on the label if you want to copy a trial.

In a double-blind trial in 46 adults, the synbiotic group's median SLEDAI-2K fell from 14 to 8 over 60 days (p<0.001), while the placebo group stayed at 9 (p=0.31) [2]. hs-CRP held steady on the synbiotic (1.8 to 2.1 mg/L) but rose on placebo (1.75 to 3.75 mg/L, p=0.005), and IL-6 fell on the synbiotic (8.76 to 6.59, p=0.02). The synbiotic group started with higher disease activity, which the authors acknowledge may have influenced the result, and the abstract reports changes within each group rather than a direct comparison.

A 2-month trial in 50 adults found that the inflammatory cytokine IL-17A and SLEDAI-2K fell within the synbiotic group compared with baseline, while the control group did not change [3]. The abstract describes the control as standard therapy alone in one place and as a placebo group in another, and gives no SLEDAI numbers. The same research group wrote the 2023 systematic review [1].

The only trial whose abstract compares groups directly on disease activity was a triple-blind trial of probiotic yogurt. Adults with mild lupus on stable immunosuppressant doses ate 200 g a day of yogurt with Lactobacillus rhamnosus and Bifidobacterium bifidum, or the same yogurt without the bacteria, for 13 weeks. Comparing 19 patients with 14, there was no significant difference in SLEDAI or disability (HAQ) between the groups [4].

Low starting disease activity left little room to improve, so this trial can't rule out a benefit in active lupus. But it is the one direct comparison available, and it was null.

A 2024 meta-analysis of 80 trials across 14 autoimmune diseases included four trials in lupus or lupus nephritis, all small Chinese-language reports of probiotic preparations added to standard treatment such as prednisone. Pooled, SLEDAI was 2.31 points lower than control (95% CI -2.48 to -2.14), IgG was lower, and two trials found higher complement C3 [5]. In the one lupus trial that compared side effects, rates were similar (31.91% vs 34.78%).

That confidence interval is very narrow for four small trials, the trials can't easily be read outside China, and none of the three English-language trials above was included. The same meta-analysis found no benefit in rheumatoid arthritis or spondyloarthritis [5]. Treat the pooled figure as a signal to test, not as a measured effect.

No English-language trial has lasted longer than 13 weeks or enrolled more than 50 people, and no trial has used flares, organ damage or kidney outcomes as an outcome. The Indonesian trial did report needing to raise steroid doses in 3 synbiotic and 8 placebo patients, but this was not a planned measure [2]. Each trial used a different product, so no product has replicated results. Much of the English-language evidence comes from one research group in Mashhad, Iran [1][3].

Standard treatment is where the strong evidence sits. The 2023 EULAR recommendations advise hydroxychloroquine for everyone with lupus, keeping maintenance steroids at 5 mg a day of prednisone or less, and adding immunosuppressants or biologics such as belimumab or anifrolumab to control disease [10].

Probiotics are unlikely to cause harm in healthy people, and side effects are usually minor [11]. In the lupus meta-analysis, adverse events were similar with and without probiotics in the one trial that compared them [5], and in the 60-day synbiotic trial one patient per group reported abdominal pain [2].

The concern in lupus is the immune system. Probiotics have been linked to a few cases of bacteraemia, fungaemia and severe infection, mostly in people who were severely ill or immunocompromised [11]. A review of reports from 2019 to 2021 counted 48 Lactobacillus infections, including endocarditis and bacteraemia, mostly in diabetic or immunocompromised patients, often with risk factors such as prosthetic heart valves; Lactobacillus rhamnosus, including strain GG, was the most common [13]. Theoretical risks also include excessive immune stimulation in susceptible people, and trials have reported safety inconsistently [12]. For people with weakened immunity or other serious illness, the World Gastroenterology Organisation advises using only strains with proven benefit for the condition being treated [11], and no strain has proven benefit in lupus. The Indonesian trial excluded pregnant and breastfeeding women [2], so there is no lupus-specific evidence for pregnancy.

No formal interaction studies exist between probiotics and lupus medicines. In the trials, probiotics were given alongside standard treatment, including stable immunosuppressants [4] and prednisone [5], without excess side effects reported. The main issue is infection risk when immunity is lowered [11][13], not a chemical interaction.